Catalent Acquires MaSTherCell Global
Press releases | February 4, 2020
Fried Frank acted as counsel to Catalent in its US$315 million acquisition of MaSTherCell Global. Catalent is a global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products. MaSTherCell Global, a company backed by Great Point Partners, SFPI-FPIM, and Orgenesis Inc., is a technology-focused cell and gene therapy contract development and manufacturing organization to leading cell therapy innovators. The transaction is expected to close in the third quarter of 2020. The Fried Frank deal team was led by corporate partners Steven Epstein and Matthew V. Soran; executive compensation & ERISA partner Amy L. Blackman; intellectual property and technology partner Amir R. Ghavi; tax partner Michael J. Alter; corporate special counsel Howard A. Fine; corporate associates Adam B. Cohen, J. Tyler Finn, Aleksandr Galinskiy; environmental associates Samuel K. Dykstra and Mary Beth Phipps; executive compensation & ERISA associates Michelle L. Roter and Samantha Rozell; litigation associate Jasen T. Fears; and tax associate Ryan L. Conley.
This communication is for general information only. It is not intended, nor should it be relied upon, as legal advice. In some jurisdictions, this may be considered attorney advertising. Please refer to the firm’s data policy page for further information.